Vol 115, No. 3, pp 463-471, March 2007

Slides:



Advertisements
Similar presentations
Chronic Kidney Disease Manju Sood GPST3. What is CKD? Chronic renal failure is the progressive loss of nephrons resulting in permanent compromise of renal.
Advertisements

1 Laws, Regulations, Standards Chapter 3 Lead Abatement for Workers Course.
Historical perspective of lead toxicity and new challenges An Industry Physician’s Perspective Eugene Shippen, M. D. CSTE 2007.
Hepatitis A and Hepatitis A Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control.
CDC Recommendations for Lead Poisoning Prevention in Newly Arrived Refugee Children Medical Provider Module U.S. Department of Health and Human Services.
A retrospective cohort study of Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life Andrew V White,
Is low-dose Aspirin use associated with a reduced risk of colorectal cancer ? a QResearch primary care database analysis Prof Richard Logan, Dr Yana Vinogradova,
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July-August 2007.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2009.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2008.
Journal Club Alcohol and Health: Current Evidence July–August 2004.
Cohort Studies.
Journal Club Alcohol and Health: Current Evidence September–October 2004.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May-June 2008.
Overly concerning and falsely reassuring?? FRAMINGHAM RISK FACTORS IN THE ED.
Use of clinical laboratory databases to enable early identification of patients at highest risk of developing end- stage kidney disease Dr David Kennedy.
Lead Health Effects Warren Silverman MD.
The Diabetic Retinopathy Clinical Research Network Repeated Intravitreous Ranibizumab Injections for DME and Risk of Sustained IOP Elevation or Need for.
Hypertensive Management in the Asymptomatic Patient: First do no harm Steven A Godwin MD, FACEP University of Florida, COM-Jacksonville Ponte Vedra 2007.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2012.
Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham.
HYPERTENSION The Alabama Department of Public Health’s Hypertension Program.
DECREASING SLEEP-TIME BLOOD PRESSURE DETERMINED BY AMBULATORY MONITORING REDUCES CARDIOVASCULAR RISK Ramón C. Hermida, PhD; Diana E. Ayala, MD, MPH, PhD;
Occupational Legislation Overview - Rest of the World
The effects of initial and subsequent adiposity status on diabetes mellitus Speaker: Qingtao Meng. MD West China hospital, Chendu, China.
Quality of Life and Depression as Determinants of Treatment Adherence in Hypertensive Leonelo E. Bautista 1 ; Paul Smith 2 ; Cynthia Colombo 2 ; Dennis.
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Yaffe K, Laffan AM, et al. Sleep-disordered Breathing, Hypoxia, and Risk of Mild Cognitive Impairment and Dementia in Older Women. JAMA.2011;306(6):
Occupational Health (North America) 18 th International Lead Conference June 2013 Robert Steinwurtzel and Thomas Hogan
Summary of Lowest Lead Levels for Lead-induced Side Effects ATSDR, US Department of Health and Human Services. Toxicological Profile for Lead, 1990.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Clinical Characteristic of Patients with Uncontrolled, Potentially Under-treated and Apparent Treatment Resistant Hypertension: NHANES 1988  Brent.
Lead Toxicity Human Health Effects Board Council of Governments April 14, 2004 Washington, DC Georges C. Benjamin, MD, FACP Executive Director American.
Red Cell Distribution Width (RDW) as a Novel Prognostic Marker in Heart Failure: Data from the CHARM Program and the Duke Databank.
Estimation of Kidney Function Richard C. Walls
Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP
® Introduction Changes in Opioid Use for Chronic Low Back Pain: One-Year Followup Roy X. Luo, Tamara Armstrong, PsyD, Sandra K. Burge, PhD The University.
Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.
Lead Exposure Among Females of Childbearing Age — United States, 2004 What Does ABLES Tell Us? Sara Luckhaupt, MD, MPH Surveillance Branch CDC, NIOSH,
Case Management 410 IAC Local health officers shall ensure the provision of case management to all children under seven (7) years of age in their.
AOEC Medical Management for Lead Exposed Adults Kathleen Fagan, MD, MPH June 27, 2007.
2012 Bunker Hill Superfund Site Coeur d’Alene Basin Blood Lead Levels Panhandle Health District Idaho Department of Environmental Quality United States.
The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial ONTARGET.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.
Key Elements of a Primary Prevention Program. Percent of Preschool Children Exceeding Selected Blood Lead Levels, NHANES II - III Pirkle JL, et al. Environ.
2007 Bunker Hill Superfund Site Coeur d’Alene Basin Blood Lead Levels Idaho Department of Health and Welfare Idaho Department of Environmental Quality.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2015.
Identifying Persons in Need of Weight-loss Treatment: Evaluation of Potential Treatment Algorithms Caitlin Mason School of Physical and Health Education.
FHM TRAINING TOOLS This training presentation is part of FHM’s commitment to creating and keeping safe workplaces. Be sure to check out all the training.
Printed by Natural History of Sun Protection Behaviors in a Cohort of Children in Colorado Nancy L. Asdigian PhD,* Lori A. Crane.
Kelsey Vonderheide, PA1.  Heart Failure—a large number of conditions affecting the structure and function of the heart that make it difficult for the.
Exjade One Year Experience Dr Khawla Belhoul Director Thalassemia Center 9 Th February 2008.
1 Subclinical thyroid dysfunction and blood pressure: a community-based study John P. Walsh, Alexandra P. Bremner, Max K. Bulsara‡, Peter O’Leary, Peter.
Contoh 1: Home Use of Paints and Petroleum Products and Risk of Childhood Leukemia Associations between childhood leukemia and parental occupational exposures.
Figure 1.1 Prevalence of CKD by stage among NHANES participants,
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
Blood Pressure and Age in Controlling Hypertension
From ESH 2016 | POS 7D: Jan Rosa, MD
Diane Jackson, PE, Hatice Zahran, MD, MPH, Greg Zarus, MS
Square-root TSH (μIU/mL) Presence vs. Absence TPO Abᵈ
by Qi Sun, Monik C. Jiménez, Mary K. Townsend, Eric B. Rimm, JoAnn E
Screening and Monitoring
The percentage of subjects with de novo development of renal function impairment (GFR
Progress and Promise in RAAS Blockade
Restoration/Remediation of Urban Soils
Type 2 diabetes: Overlap of clinical conditions
Correlation between endothelial function and hypertension
Characteristics of Study Subjects and Events, According to the Quintile of Exposure to Fine Particulate Matter (PM2.5)* - Part I Kristin A. Miller et al.
Presentation transcript:

Vol 115, No. 3, pp , March 2007

OSHA Lead Standards: Medical removal not mandatory until blood lead concentrations ≥ 50 µg/dL Health effects of lead at low dose warrant a reappraisal of the levels of lead exposure that may be safely tolerated in the workplace. Chronic effects of cumulative dose Acute effects of recent dose hypertension decrements in renal function cognitive dysfunction adverse reproductive outcome

Nawrot et al, 2002 Schwartz, 1995 Meta-analyses:  PbB 5  10 µg/dL =  1.0 or 1.25 mmHg in systolic blood pressure

The Relationship of Bone and Blood Lead to Hypertension. The Normative Aging Study Hu H et al, JAMA 1996; 275: Case control study: 146 hypertensive men; 444 controls selected from large, ongoing prospective study of aging. Mean age = 66.6 ±7.2 y Exposure reflects that of general population. Mean PbB = 6.3 ug/dL Final logistic model (backward elimination) yielded 3 significant risk factors for hypertension: Body mass index Family history of hypertension Tibia bone lead concentration From the lowest quintile of bone lead to the highest quintile, the odds of being hypertensive increased by 50 % O.R. = 1.5 (95% C.I )

Impairment of renal function with increasing blood lead concentration in the general population Staessen JA et al. NEJM 327:151-6; 1992 Random population sample of 965 men and 1016 women (age 20 to 88) Blood lead range ug/dL; geometric mean (GM) ≈ 10 ug/dL Significant correlation between age- adjusted creatinine clearance and blood lead Relationship persisted after excluding subjects with occupational Pb exposure, or those with highest tercile of PbB ( GM = 18.4 ug/dL)

Bone lead concentration predicts decrements in cognitive function in older adults 1. Baltimore Memory Study (Shih et al, 2006) N = 991 randomly selected, sociodemographically diverse community dwelling adults, aged 50 to 70 yrs Mean PbB = 3.5 ± 2.2 µg/dL Tibia lead:  visuoconstruction on neuropsych testing  13 ppm equivalent impact of 4.8 years of age 2. Normative Aging Study (Weisskopf et al, 2007) N = 1089 older, mainly white men, mean age 68.7 ± 7.4 yrs. Repeat neuropsych testing over ≈ 3.5 yr interval Median PbB = 5 µg/dL (IQR 3 - 6) Tibia lead: longitudinal  visuospatial performance (N = 761)

Blood Lead Levels Measured Prospectively and Risk of Spontaneous Abortion [Borja-Aburto et al, 1999] 562 of 668 women followed through week 20; (16% loss to follow-up) Average blood lead at enrollment: 11 ug/dL Cases (n=35) PbB = 12 ug/dLControls (n=60) PbB = 10ug/dL PbB level (ug/dL)Odds Ratio < [referent] ≥ test for trend p = 0.021; for  PbB of 5 µg/dL, O.R. = 1.8 (C.I. 1.1, 3.1)

Mexico City Prospective Lead Study (Schnaas et al 2006) 3rd Trimester PbB = 7.8 µg/dL Every doubling of PbB associated with IQ  2.7 pts at yrs of age N = 150

BLL (µg/dL)Management < 5None indicated 5 - 9Discuss health risks Reduce Pb exposure for women who are or may become pregnant Decrease lead exposure. Increase biological monitoring. Consider removal from exposure to avoid long term risks if exposure control over an extended period does not decrease BLL < 10, or if medical condition present that increases risk with continued exposure Remove from exposure if repeat BLL measured in 4 weeks remains ≥ 20

BLL (µg/dL)Management Remove from lead exposure Remove from lead exposure Refer for prompt medical evaluation Consider chelation for BLL >50 with significant symptoms or signs ≥ 80Remove from lead exposure Refer for immediate/urgent medical evaluation Probable chelation therapy

CategoryRecommended medical surveillance All lead-exposed workers Baseline/preplacement H&P, baseline BLL, serum creatinine BLL < 10 BLL q month for first 3 mo. or if ∆ to higher exp., then BLL q 6 mo. If BLL  ≥ 5, evaluate exposure and protective measures. Increase monitoring if indicated BLL As above for BLL < 10, plus: BLL q 3 months Evaluate exposure, controls, work practices Consider removal Revert to BLL q 6 mo after 3 BLLs < 10 BLL ≥ 20 Remove from exposure if repeat BLL measured in 4 weeks remains ≥ 20, or if first BLL ≥ 30 Monthly BLL Consider return to lead work after 2 BLLs <15 a month apart, then monitor as above

Surveillance recommendations apply to all potential lead exposed workers, even in absence of documented elevations in air lead levels. Routine measurement of zinc protoporphyrin not indicated With potential exception of annual BP measurement and risk factor questionnaire, medical evaluations unnecessary for workers maintaining BLL < 20 µg/dL. Annual worker education about lead hazards is recommended.

Chelation for lead intoxication in adults BLLs ≥ 100 µg/dL almost always warrant chelation. BLL µg/dL, with or without symptoms, can be considered for chelation, as may some symptomatic individuals with blood lead concentrations of Chelation not recommended for asymptomatic individuals with low blood lead concentrations